GPE – Page 21 – Talk Bio

Fujifilm Diosynth Biotechnologies, $1.2 billion expansion, North Carolina, Holly Springs, 1/400 jobs, Biopharmaceutical manufacturing, End-to-end cell culture CDMO facility, Japanese investment

Eli Lilly’s State Law Attempt to Halt Florida Compounding Pharmacy’s Tirzepatide Sales Dismissed

1 year ago talkbio0Tagged Cosmetic Act, eli lilly, FDCA, Florida compounding pharmacy, Frivolous lawsuits, Judge Roy Altman, Mounjaro/ Zepbound, RXCompoundStore.com, tirzepatide

Eli Lilly, Florida compounding pharmacy, RXCompoundStore.com, Tirzepatide (Mounjaro/ Zepbound), Judge Roy Altman, Federal Food/ Drug/ and Cosmetic Act (FDCA), Frivolous lawsuits

Sanofi Resolves 4,000 Zantac Cancer Claims in US State Courts

1 year ago talkbio0Tagged Cancer Lawsuits, Heartburn Drug, sanofi, US State Courts, Zantac

Sanofi, Zantac, Heartburn Drug, Cancer Lawsuits, Settlement Agreement, US State Courts

Genmab Acquires ProfoundBio for $1.8 Billion to Challenge AbbVie’s Elahere in ADC Market

1 year ago talkbio0Tagged AbbVie's, Acquisition (action), Antibody-Drug Conjugates, competition, Elahere, FOLR1 gene, FOLR1 protein, human, Genmab, Midphase clinical trials, ProfoundBio, Rina-S, Rinatabart sesutecan

Genmab, ProfoundBio, $1.8 billion acquisition, Antibody Drug Conjugates (ADCs), Competition with AbbVie’s Elahere, Rinatabart sesutecan (Rina-S), Folate Receptor Alpha (FRα), Midphase clinical trials

Walgreens Takes $6 Billion Hit from VillageMD Investment Amid Strategic Review

1 year ago talkbio0Tagged Clinic, Cost Savings Plan, Investment Value Decline, Quarter 2, strategic review, VillageMD, Walgreens, Write-down

Walgreens, VillageMD, Quarter 2, $6 billion loss, Write-down, Investment Value Decline, Strategic Review, Cost Savings Plan, Underperforming Clinics Closure

FDA Grants Emergency Authorization for Invivyd’s Pemgarda Antibody Prophylactic Against COVID-19 in Immunocompromised Individuals

1 year ago talkbio0Tagged Adolescent (age group), Adults/, Approved, Condoms, Male, COVID19 (disease), Emergency Use Authorization, Half-Life Extended Monoclonal Antibody, immune compromise, Immunocompromised Host, Invivyd, Moderate (severity modifier), Pemgarda, pemivibart, Pre-Exposure Prophylaxis, Prophylactic treatment, Severe (severity modifier), United States Food and Drug Administration, VYD222

Invivyd, Pemgarda (pemivibart; formerly VYD222), Half-Life Extended Monoclonal Antibody, COVID-19 Prophylactic, Immunocompromised Patients, Emergency Use Authorization (EUA), FDA Approval, Moderate to Severe Immune Compromise, Pre-exposure Prophylaxis (Prevention) of COVID-19 in Adults/ Adolescents